source
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.
- Axiom Biosciences pursues Hong Kong IPO and novel stem cell platform amid funding challengesAxiom Biosciences is charting an unconventional financing path by targeting a public listing in Hong Kong, with a long‑term goal of listing on the Nasdaq. The company is developing multiple drug d…